Overview
Neurópixel Therapeutics develops minimally invasive, light-based neuromodulation implants that use optogenetic stimulation to treat refractory epilepsy and chronic pain.
More in Neuromodulation
Latest industry news
Noninvasive Brain Interface Uses AI Suggestions to Triple Communication Speed
2026-11-21 · Research
Zhongke Borui Closes $15M Round to Scale Brain-Computer Interface Hardware in China
2026-11-20 · Funding
ALS Community Gains a Formal Voice in Brain-Computer Interface Development
2026-11-19 · Policy
Science Corporation Closes $400M Round to Push Brain-Computer Interface Technology Into the Clinic
2026-11-18 · Funding
Company details
Category
⚡ Neuromodulation
Location
San Diego, CA
Funding
Series A — $22M
Website
neurópixeltherapeutics.comListed
2026-09-21
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →